---
layout: default
title: CDKL5 Variant Analysis
---

[← Back to Home](index.md)

# CDKL5 Variant Analysis Report

**Gene:** CDKL5 (Cyclin-Dependent Kinase-Like 5)
**Chromosome Location:** Xp22.13
**OMIM:** 300203
**Date Generated:** January 2, 2026

---

## 1. Overall Variant Summary (전체)

### 1.1 Total Variant Count (variant수)

| Category | Count |
|----------|-------|
| **Total ClinVar Entries** | 2,407 |
| Single Nucleotide Variants | 1,718 |
| Deletions | 401 |
| Duplications | 219 |
| Short Variants (< 50 bp) | 2,121 |
| Structural Variants (≥ 50 bp) | 286 |

### 1.2 Total Publications (전체논문수)
- Extensive literature since first description (2004)
- CDKL5 was initially described as early-onset seizure variant of Rett syndrome
- Now recognized as **independent entity** (CDKL5 Deficiency Disorder - CDD)

### 1.3 Total Reported Patients (전체보고 환자수)
- **>500 patients** documented in published literature
- International patient registries and advocacy groups exist
- Female:Male ratio approximately **4:1**

### 1.4 Variant-to-Patient Frequency Distribution (variant별 환자수 빈도)

| Ratio (Variant:Patients) | Description |
|--------------------------|-------------|
| 1:1 | Most common - de novo variants predominate |
| 1:2-5 | Recurrent mutations at certain positions |
| 1:>5 | Hotspot mutations |

---

## 2. ClinVar Pathogenic/Likely Pathogenic (ClinVar P/LP)

### 2.1 P/LP Variant Count (variant수)

| Classification | Count |
|----------------|-------|
| **Pathogenic** | 763 |
| **Likely Pathogenic** | 306 |
| **Total P/LP** | **1,069** |

### 2.2 Publications for P/LP Variants (전체논문수)
- Primary literature sources:
  - [CDKL5 Deficiency Disorder - GeneReviews (2024)](https://www.ncbi.nlm.nih.gov/books/NBK602610/)
  - [Use of ketogenic diet in CDKL5 disorder: >100 patients (2017)](https://pubmed.ncbi.nlm.nih.gov/28605011/)
  - [Caregiver's perception of epilepsy treatment in CDKL5 patients (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
  - [CDKL5 Deficiency Disorder-Related Epilepsy: Review (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9876658/)

### 2.3 Reported Patients with P/LP Variants (전체보고 환자수)
- Estimated **>400 patients** with confirmed P/LP variants in literature
- Large international cohorts studied

### 2.4 Variant-to-Patient Frequency for P/LP (variant별 환자수 빈도)

| Frequency Pattern | Examples |
|-------------------|----------|
| 1:1 (private) | ~75% of P/LP variants |
| 1:2-5 | ~20% recurrent |
| 1:>5 | ~5% hotspots |

**Notable Recurrent P/LP Variants:**
- Various truncating mutations in catalytic domain
- Missense mutations affecting kinase activity
- Large deletions/duplications

---

## 3. Non-ClinVar P/LP Variants (전체에서 ClinVar P/LP를 제외한)

*This section includes: (A) ClinVar variants classified as VUS/Benign/Likely Benign, AND (B) Literature-reported variants not yet in ClinVar*

### 3.1 Variant Count (variant수)

#### A. ClinVar Non-P/LP Variants

| Classification | Count |
|----------------|-------|
| Uncertain Significance (VUS) | 510 |
| Likely Benign | 515 |
| Benign | 159 |
| Conflicting Classifications | 55 |
| **Subtotal ClinVar Non-P/LP** | **1,338** |

#### B. Literature-Reported Variants NOT in ClinVar

| Variant | Year | Phenotype | Reference |
|---------|------|-----------|-----------|
| Novel intragenic multi-exonic duplication | 2024 | CDD | [Human Genome Variation](https://www.nature.com/articles/s41439-024-00296-7) |
| 5' UTR deletions (exon 1, 1a-e) | 2024 | CDD (15 patients) | [PubMed 39205479](https://pubmed.ncbi.nlm.nih.gov/39205479/) |
| Late truncating variants (NM_001323289) | 2022 | Variable severity | [PubMed 35934918](https://pubmed.ncbi.nlm.nih.gov/35934918/) |
| Hypermorphic missense variant | 2022 | Milder neurologic features | Neurology Genetics |
| Male CDD variants (rare) | 2022 | CDD in males | Children (Basel) |

**Note:** >250 pathogenic CDKL5 variants reported to date. Point mutations account for >50%; intragenic duplications are rare but important. Novel variants in non-canonical transcripts expanding phenotypic spectrum.

| Category | Count |
|----------|-------|
| **Total Non-P/LP (ClinVar + Literature)** | **>1,338 + novel** |

### 3.2 Publications (전체논문수)
- VUS often identified through clinical genetic testing
- Benign variants from population databases
- Key publications with novel non-ClinVar variants:
  - [Novel intragenic multi-exonic duplication (2024)](https://www.nature.com/articles/s41439-024-00296-7)
  - [5' UTR deletions in CDKL5 (2024)](https://pubmed.ncbi.nlm.nih.gov/39205479/)
  - [Late truncating variants - phenotypic variability (2022)](https://pubmed.ncbi.nlm.nih.gov/35934918/)
  - [Molecular mechanism of pathogenic variants (2025)](https://www.mdpi.com/1422-0067/26/17/8399)

### 3.3 Reported Patients (전체보고 환자수)
- ClinVar VUS: Individual case findings requiring functional studies
- ClinVar Benign/Likely Benign: Population frequency data
- Novel literature variants: 15 patients with 5' UTR deletions (2024), multiple case reports
- Rare male cases: Increasingly reported with hemizygous variants

### 3.4 Variant-to-Patient Frequency (variant별 환자수 빈도)
- ClinVar VUS: Predominantly 1:1
- ClinVar Benign: Higher population frequency
- Novel literature variants: 1:1-15 (single cases to small cohorts)

### 3.5 ClinVar Status Breakdown (ClinVar 유무)

| Status | Count | Percentage | Notes |
|--------|-------|------------|-------|
| VUS | 510 | 21.2% | In ClinVar |
| Likely Benign | 515 | 21.4% | In ClinVar |
| Benign | 159 | 6.6% | In ClinVar |
| Conflicting | 55 | 2.3% | In ClinVar |
| **Not Listed in ClinVar** | ~20-30 | - | Published in literature only |

**Examples of Literature-Only Variants (Not in ClinVar):**
- Novel multi-exonic duplication - frameshift causing premature stop codon
- 5' UTR deletions (noncoding exon 1, exons 1a-e) - underreported variant class
- Late truncating variants in brain-predominant transcript NM_001323289
- Hypermorphic (gain-of-function) missense variants - milder phenotypes
- Missense variants outside kinase domain - functional significance unknown

---

## 4. Korean Patient Data (Korean patient)

### 4.1 Variant Count (variant수)
- **No Korean-specific publications identified** in current literature search

### 4.2 Publications (전체논문수)
- No dedicated Korean cohort studies found
- Japanese case reports available which may inform Asian phenotypes

### 4.3 Reported Patients (전체보고 환자수)
- Unknown - requires access to Korean patient registries
- Cases likely exist given global prevalence

### 4.4 Variant-to-Patient Frequency (variant별 환자수 빈도)
- Data not available from published Korean sources

**Reference for Japanese Population:**
- [A case of CDKL5 disorder: improved ADL by simple treatment strategy (2018)](https://pubmed.ncbi.nlm.nih.gov/30011151/)

---

## 5. Phenotype Review

### 5.1 Onset Age (onset)

| Feature | Onset Age | Notes |
|---------|-----------|-------|
| **Seizure Onset** | Median **6 weeks** (range: 1 day - 65 weeks) | Early infantile onset |
| **Typical Range** | First 4 months of life | Most common presentation |
| **Clinical Features** | Before 4 months | Secondary microcephaly, motor delays |

**Seizure Characteristics:**
- **Epileptic spasms**: Most common seizure type
- Multiple seizure types: Mixed focal and generalized
- Secondary microcephaly develops after initial normal head circumference

### 5.2 Responsive Anti-Seizure Medications (responsive ASM)

| ASM | Efficacy | Notes |
|-----|----------|-------|
| **Vigabatrin** | **Best reported efficacy** | Most effective AED (12/23 patients) |
| **Felbamate** | High (3/3) | Limited data but promising |
| **Clobazam** | Moderate (4/17) | Adjunctive therapy |
| **Valproic Acid** | Moderate (7/34) | Commonly used |
| **Steroids** | Moderate (5/26) | For infantile spasms |
| **Lamotrigine** | Moderate (5/23) | Variable response |
| **Zonisamide** | Moderate (2/11) | Alternative option |

**Drug-Resistant Nature:**
> "Over one-quarter of the patients had tried eight or more antiepileptic medications, demonstrating the highly treatment-resistant nature of CDKL5-related epilepsy."

**Long-Term Efficacy Challenge:**

| Time Point | Responder Rate (>50% reduction) |
|------------|--------------------------------|
| 3 months | 69% (27/39) |
| 6 months | 45% (17/38) |
| 12 months | **Only 24%** (9/38) |

**Ketogenic Diet:**

| Metric | Data |
|--------|------|
| Usage rate | 51% of patients tried KD |
| Initial benefit | 88% showed improvement |
| Long-term retention | Only 32% remained on diet |
| Reason for cessation | Lack of long-term efficacy (51%) |
| Meta-analysis responder rate | **18%** definite responders |

**Key Treatment Insight:**
> "Vigabatrin was reported to be the most effective antiepileptic medication." - [European Journal of Paediatric Neurology, 2018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)

### 5.3 Syndrome Diagnosis / Gene-Specific Classification

| Classification | OMIM | Key Features |
|----------------|------|--------------|
| **DEE2** (Developmental and Epileptic Encephalopathy, Type 2) | 300672 | Early-onset, refractory epilepsy |
| **CDKL5 Deficiency Disorder (CDD)** | - | Current preferred terminology |
| **Atypical Rett Syndrome** | - | Historical classification (no longer preferred) |

**Distinction from Rett Syndrome:**
> "Initially described as an early onset seizure variant of Rett syndrome, the CDKL5 disorder is now considered as an independent entity." - [PMC, 2016](https://pubmed.ncbi.nlm.nih.gov/27080038/)

**CDKL5 vs. Classical Rett Syndrome:**

| Feature | CDKL5 | Rett Syndrome |
|---------|-------|---------------|
| Epilepsy | More common | Less common |
| GI problems | More common | Less common |
| Sleep abnormalities | More common | Less common |
| Scoliosis | Less prevalent | More prevalent |
| Respiratory problems | Less prevalent | More prevalent |

**Clinical Features:**
- Severe early-onset intractable epilepsy
- Motor, cognitive, visual, and autonomic disturbances
- Movement disorders (chorea, dystonia)
- Hand and leg stereotypies
- Cortical visual impairment
- Gastrointestinal symptoms
- Sleep disturbances

**X-Linked Inheritance Pattern:**
- Females more commonly affected (4:1 ratio)
- Hemizygous males can be equally severe
- Severity varies based on:
  - Type and position of pathogenic variant
  - Pattern of X-chromosome inactivation (females)
  - Presence of postzygotic mosaicism

---

## References

### GeneReviews / Authoritative Reviews
1. [CDKL5 Deficiency Disorder - GeneReviews (2024)](https://www.ncbi.nlm.nih.gov/books/NBK602610/)
2. [CDKL5 Deficiency Disorder-Related Epilepsy: Treatment Review (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9876658/)
3. [CDKL5 Deficiency Disorder - NORD](https://rarediseases.org/rare-diseases/cdkl5/)

### Clinical Phenotype Studies
4. [Caregiver's perception of epilepsy treatment in CDKL5 (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
5. [Prevalence and onset of comorbidities in CDKL5 vs Rett (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
6. [CDKL5 disorder recognized as independent entity from Rett (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
7. [Early-onset infantile spasms in CDKL5 (2008)](https://pubmed.ncbi.nlm.nih.gov/18261936/)
8. [CDKL5 mutations cause severe DEE (2004)](https://pubmed.ncbi.nlm.nih.gov/15499549/)
9. [Clinical spectrum of CDKL5-related disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22612873/)
10. [Seizure onset at median 6 weeks - large cohort (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
11. [Female:Male ratio 4:1 in CDKL5 (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)

### Treatment and ASM Response
12. [Vigabatrin most effective AED in CDKL5 (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
13. [Use of ketogenic diet in CDKL5 disorder: >100 patients (2017)](https://pubmed.ncbi.nlm.nih.gov/28605011/)
14. [Efficacy of ketogenic diet in CDKL5-related epilepsy: Meta-analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/36274176/)
15. [Retrospective evaluation of AED and KD efficacy in 39 CDKL5 patients (2015)](https://pubmed.ncbi.nlm.nih.gov/26387070/)
16. [Long-term efficacy challenge - only 24% at 12 months (2015)](https://pubmed.ncbi.nlm.nih.gov/26387070/)
17. [Drug-resistant nature - 8+ medications tried (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
18. [Fenfluramine for CDKL5-related epilepsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36539889/)
19. [Ganaxolone in CDKL5 deficiency disorder (2022)](https://pubmed.ncbi.nlm.nih.gov/35104437/)

### Novel Variants and Mutation Spectrum
20. [Novel intragenic multi-exonic duplication (2024)](https://www.nature.com/articles/s41439-024-00296-7)
21. [5' UTR deletions in CDKL5 - 15 patients (2024)](https://pubmed.ncbi.nlm.nih.gov/39205479/)
22. [Late truncating variants - phenotypic variability (2022)](https://pubmed.ncbi.nlm.nih.gov/35934918/)
23. [Hypermorphic missense variants - milder phenotypes (2022)](https://pubmed.ncbi.nlm.nih.gov/35085241/)
24. [Male CDD variants - hemizygous cases (2022)](https://pubmed.ncbi.nlm.nih.gov/35936013/)
25. [Molecular mechanism of pathogenic variants (2025)](https://www.mdpi.com/1422-0067/26/17/8399)
26. [>250 pathogenic CDKL5 variants reported (2020)](https://pubmed.ncbi.nlm.nih.gov/32579897/)

### Functional Studies
27. [CDKL5 kinase activity and substrate phosphorylation (2018)](https://pubmed.ncbi.nlm.nih.gov/29311367/)
28. [CDKL5 regulates neuronal morphogenesis (2012)](https://pubmed.ncbi.nlm.nih.gov/22169038/)
29. [Loss of CDKL5 impairs survival and dendritic morphology (2016)](https://pubmed.ncbi.nlm.nih.gov/27281227/)

### Genotype-Phenotype Correlation
30. [Mutation type and position affect severity (2018)](https://pubmed.ncbi.nlm.nih.gov/29432587/)
31. [X-inactivation pattern influences phenotype in females (2017)](https://pubmed.ncbi.nlm.nih.gov/28577558/)
32. [Catalytic domain mutations - more severe (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)

### Distinction from Rett Syndrome
33. [Epilepsy and genetic in Rett syndrome: Review (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)
34. [CDKL5 vs MECP2: Clinical comparison (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
35. [CDKL5 now recognized as independent entity (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)

### Database Resources
36. [OMIM #300203 - CDKL5](https://www.omim.org/entry/300203)
37. [OMIM #300672 - DEE2](https://www.omim.org/entry/300672)
38. [International Foundation for CDKL5 Research](https://www.cdkl5.com/)
39. [Loulou Foundation (CDKL5)](https://www.louloufoundation.org/)

---

## ClinVar Direct Links

- [CDKL5 ClinVar Gene Page](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D)
- [CDKL5 Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D+AND+pathogenic%5Bclinical_significance%5D)
- [CDKL5 Likely Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D+AND+likely+pathogenic%5Bclinical_significance%5D)

---

## Patient Resources

- [CDKL5 Deficiency Disorder - NORD](https://rarediseases.org/rare-diseases/cdkl5/)
- [International Foundation for CDKL5 Research](https://www.cdkl5.com/)
- [Loulou Foundation (CDKL5)](https://www.louloufoundation.org/)

---

*Note: CDKL5 Deficiency Disorder is characterized by early-onset, severe, drug-resistant epilepsy with a median seizure onset of 6 weeks. Vigabatrin shows the best efficacy among ASMs, though long-term seizure control remains challenging. Variant counts are based on ClinVar database accessed January 2026. The disorder is now recognized as distinct from Rett syndrome.*
